Possibilities of glucagon-like peptide-1 agonists in women of fertile and postmenopausal age against a background of obesity
Litsenziya: cc-by
Annotatsiya
The purpose. Optimization of treatment of patients with non-alcoholic fatty liver disease associated with insulin resistance with the GLP-1 receptor agonist liraglutide. Materials and methods: The results of analyses of 139 patients aged 25-60 years with varying degrees of obesity were presented. The study included women from two age groups: those of childbearing age (25-44 years) (n-47) and those of perimenopausal age (45-60 years) (n-55). 37 apparently healthy women served as a control group. The following results were obtained: The inclusion of GLP-1 agonists in the treatment of women from different age groups, with increasing doses starting from 0.6 mg each week and reaching a drug level of 2.4 mg once a week, significantly improved their overall condition. Body weight decreased significantly (p<0.01), the range of physical activity expanded, patients tolerated low-calorie diets more easily, and the psycho-emotional status of women in both groups improved considerably.
Hali tarjima qilinmagan